Clinical Trial Update: A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1, open-label, dose-escalation study of ANG1005 in patients with advanced solid tumors, with and without brain m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Solid Tumors

Drugs mentioned

• ANG1005 (GRN1005)

Snippet

Sponsor: Angiochem Inc | Conditions: Advanced Solid Tumors With and Without Brain Metastases | Phase 1 | Status: COMPLETED